QUELL THERAPEUTICS
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto S... anchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
QUELL THERAPEUTICS
Social Links:
Industry:
Association Biotechnology Education Health Care
Founded:
2019-03-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.quell-tx.com
Total Employee:
101+
Status:
Active
Total Funding:
240.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt WordPress Content Delivery Network Nginx Euro Microsoft Exchange Online
Similar Organizations
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
Caraway Therapeutics
Rheostat Therapeutics is a bio therapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Ridgeback Capital
Ridgeback Capital investment in Series B - Quell Therapeutics
Jeito Capital
Jeito Capital investment in Series B - Quell Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Quell Therapeutics
Point72
Point72 investment in Series B - Quell Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Series B - Quell Therapeutics
British Patient Capital
British Patient Capital investment in Series B - Quell Therapeutics
Tekla Capital Management
Tekla Capital Management investment in Series B - Quell Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Quell Therapeutics
SV Health Investors
SV Health Investors investment in Series B - Quell Therapeutics
Monashee Investment Management
Monashee Investment Management investment in Series B - Quell Therapeutics
Official Site Inspections
http://www.quell-tx.com Semrush global rank: 3.59 M Semrush visits lastest month: 4.02 K
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
